In unusual circumstances, Ipsen has been given the green light for its odevixibat drug for severe itching (pruritus) in patients with rare liver disease Alagille syndrome (ALGS) in the EU – for ...

Paige and Nora Wagner of Duluth don’t share the typical sisterly bond. They’re bonding over what most would see as a situation that could bring anyone down. “I couldn’t see in the dark. So, my mom ...

Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Ipsen is currently not running studies of odevixibat in PBC, but has a phase 3 programme on the go in biliary ...

1.7% of adverse events associated with disease-modifying therapies were atypical while 3.1% were unusually severe Disease-modifying therapies are generally well-tolerated in patients with multiple ...

Cirrhosis of the liver poses a significant health challenge worldwide. With no known cure, it requires comprehensive management to slow liver damage, alleviate symptoms and prevent potential ...